Welcome to our dedicated page for Alzamend Neuro SEC filings (Ticker: ALZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alzamend Neuro, Inc. (ALZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Alzamend Neuro is a clinical-stage biopharmaceutical company whose common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Capital Market under the symbol ALZN, as noted in multiple Form 8-K filings.
Through this page, readers can review Alzamend Neuro’s current reports on Form 8-K, which cover a range of material events. Recent 8-K filings have disclosed unregistered sales of equity securities upon conversion of Series B convertible preferred stock into common stock, Certificates of Elimination for Series A, Series B and Series C convertible preferred stock, audited financial results furnished via press release, and corporate developments such as the passing of a director. These filings also confirm the company’s status as an emerging growth company and list its Nasdaq trading information.
In addition to 8-Ks, investors may consult Alzamend Neuro’s annual report on Form 10-K and other periodic reports, which are referenced in the company’s press releases. These documents typically include details on its clinical-stage pipeline (AL001 and ALZN002), licensing arrangements with the University of South Florida Research Foundation, Inc., risk factors and financial condition.
On Stock Titan, SEC documents are paired with AI-powered summaries that explain the key points of each filing in plain language. Users can quickly see what a particular 8-K, 10-K or other report means for Alzamend Neuro’s capital structure, clinical programs or governance without reading every page. Filings are updated as they appear on EDGAR, and insider or equity-related disclosures, such as unregistered sales of securities, can be reviewed in context with the company’s broader regulatory history.
Milton C. Ault III, a director and 10% owner of Alzamend Neuro (ALZN), reported multiple transactions on Form 4. On 07/23/25, his affiliate Ault Lending, LLC converted 332.7553 Series B preferred shares into 143,429 common shares at an effective price of $2.32. The same day it sold 59,516 shares at an average $2.9502; a further 9,621 shares were sold on 07/24/25 at $2.9349.
Following the transactions, Ault Lending holds 82,552 common shares. Including other entities controlled by Mr. Ault (direct 1,843; Ault Life Sciences Inc. 11,068; Ault Life Sciences Fund LLC 61), his aggregate beneficial ownership is ≈95,524 common shares. Derivative positions remain significant: 1,767.2447 Series B preferred shares (no expiration) and 45,569 warrants with strike prices ranging from $108 to $4,050 expiring 2025-2029.
The filing shows a net reduction of roughly 69,137 shares (-42% of the 07/23 conversion) in Ault Lending’s indirect stake. While the conversion eliminates some preferred stock—simplifying the capital structure—the concurrent sales by a large insider can be viewed as a bearish signal for near-term sentiment.
Alzamend Neuro, Inc. (ALZN) has filed an amended Form 144 (Form 144/A) disclosing the intent of an undisclosed shareholder to sell 939,281 shares of common stock through broker E*TRADE Financial on or about 14 July 2025 on the NASDAQ exchange. The filing lists an aggregate market value of US $3,005,699.20 for the proposed sale. For context, the company reports 2,896,432 shares outstanding, meaning the planned disposition represents roughly one-third of the free-trading equity base, a size that can materially influence trading liquidity and share-price dynamics.
The notice also details the historical acquisition of the securities: purchases span private placements, IPO participation, open-market buys, warrant exercises and a sizable 905,172-share commitment tied to Series B convertible preferred stock, plus 25,804 shares available via warrants. Although these convertible and warrant positions are not part of the current sale, their disclosure signals additional potential share supply.
Within the past three months the same party (identified in the filing as Ault Lending, LLC) sold 1,213 shares for gross proceeds of $6,138. No material adverse information is represented, and the seller certifies compliance with Rule 144.
Key takeaways for investors: (1) the block size is large relative to the float, introducing a possible overhang; (2) the transaction is a secondary sale—no new capital accrues to the company; (3) additional convertible and warrant holdings could expand the float further if exercised or converted. The filing is procedural, but the magnitude of the proposed sale makes it noteworthy for liquidity and near-term price action.